Arrowhead Pharmaceuticals, Inc.ARWRNASDAQ
Loading
Net Income Growth AcceleratingAccelerating
Percentile Rank97
3Y CAGR+64.4%
5Y CAGR+32.1%
Year-over-Year Change
Year-over-year net income growth rate
3Y CAGR
+64.4%/yr
Quarterly compound
5Y CAGR
+32.1%/yr
Recent acceleration
Percentile
P97
Near historical high
vs 5Y Ago
4x
Strong expansion
Streak
2 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 229.73% |
| Q3 2025 | 86.45% |
| Q2 2025 | -147.31% |
| Q1 2025 | 314.02% |
| Q4 2024 | -1.49% |
| Q3 2024 | 0.15% |
| Q2 2024 | -36.31% |
| Q1 2024 | 5.69% |
| Q4 2023 | -21.14% |
| Q3 2023 | -6.54% |
| Q2 2023 | -311.50% |
| Q1 2023 | 217.79% |
| Q4 2022 | 51.67% |
| Q3 2022 | -18.69% |
| Q2 2022 | -262.39% |
| Q1 2022 | 170.57% |
| Q4 2021 | 0.79% |
| Q3 2021 | -111.78% |
| Q2 2021 | -11.58% |
| Q1 2021 | -29.36% |
| Q4 2020 | 57.19% |
| Q3 2020 | -255.84% |
| Q2 2020 | 31.38% |
| Q1 2020 | -642.09% |
| Q4 2019 | -122.84% |
| Q3 2019 | -42.44% |
| Q2 2019 | -14.90% |
| Q1 2019 | 98.53% |
| Q4 2018 | 211.86% |
| Q3 2018 | 31.04% |
| Q2 2018 | -4.85% |
| Q1 2018 | -12.77% |
| Q4 2017 | -22.99% |
| Q3 2017 | -94.43% |
| Q2 2017 | 8.65% |
| Q1 2017 | 50.00% |
| Q4 2016 | 45.61% |
| Q3 2016 | -14.42% |
| Q2 2016 | 6.70% |
| Q1 2016 | -8.05% |